Trial Profile
An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 14 Aug 2018 New trial record